ChemML
AI platform for small molecule drug discovery integrating proprietary binding and functional assays
Platform · On PremiseCompany source
Company profile
About insitro
insitro uses machine learning and data at scale to decode the complexities of biology and unlock transformative new medicines.
Company description insitro official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Work at insitro?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- amyotrophic lateral sclerosis (ALS)
- liver fat accumulation (MASLD)
- metabolic diseases
- metabolic dysfunction-associated steatohepatitis (MASH)
- neurodegeneration
- neuroscience
- obesity
- oncology
Who it serves
- Pharma
Deployment & integration
On Premise deployment with recorded integration context.
Geographic context
MarketsUnited Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Acquired CombinAbleAI to complete full-stack modality-agnostic AI platform (TherML). Received $25M milestone payments from Bristol Myers Squibb for ALS target discovery. Completed first AI-enabled human genetics study of brown adipose tissue. Extended collaborations with Bristol Myers Squibb and Eli Lilly. Nominated new ALS targets. Presented MASH data at ADA 2026.
Partnerships
Recorded partners
- Bristol Myers Squibb
- Eli Lilly and Company
- INSIGHT at Moorfields Eye Hospital
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
insitro ML-driven Platform
AI/ML platform integrating cellular and clinical data to redefine disease and accelerate drug discovery
Platform · On PremiseCompany source
POSH Platform
Pooled CRISPR screening platform with self-supervised deep learning for gene function inference
Platform · On PremiseCompany source
TherML
Full-stack, modality-agnostic AI platform for drug discovery and design across all major drug modalities
Platform · On PremiseCompany source
Virtual Human Platform
AI-driven platform for identifying key biological drivers and disease-modifying therapeutic targets
Platform · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Using Days Alive and Out of Hospital as the Study Endpoint in Cardiovascular Heart Failure Clinical Trials.JACC. Heart failure · Jul 1, 2026
A versatile multi-components mixed model for bacterial-Genome Wide association studies.Nature communications · May 7, 2026
SEC-seq reveals translation-focused metabolic strategies for high IgG productivity in clonal CHO cells.bioRxiv : the preprint server for biology · Apr 17, 2026
Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology Trials.JCO clinical cancer informatics · Apr 1, 2026
Functional dissection of complex trait variants at single-nucleotide resolution.Nature · Feb 25, 2026
PertSpectra: Interpretable Matrix Factorization for Predicting Functional Impact of Genetic Perturbation Experiments.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · Jan 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
15% body-weight reduction
BAT-01 knockdown in preclinical models through peripheral adipose beiging, preserving lean mass
Anti-fibrotic signal beyond liver-fat reduction
AI-discovered MASH candidate in preclinical studies
Eli Lilly and Company
Strategic collaboration to advance novel treatments for metabolic diseases using machine learning-powered platform
Support for IND-enabling studies for first set of pipeline programs from insitro's platform
Bristol Myers Squibb
Discovery of novel ALS therapeutic targets using insitro's Virtual Human platform and ChemML platform
$25 million in milestone payments received for achievement of discovery milestones and selection of first novel genetic target for ALS
INSIGHT at Moorfields Eye Hospital
Collaboration to expand research efforts in neurodegeneration using world's largest bioresource of eye images
Development of new AI foundation model to boost drug discovery in neurodegeneration
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Daphne Koller
Founder and CEO
Stephen Meadows
Associate Director, Administration | Executive Assistant to the CEO
Casey Chance
Staff Software Engineer
Eddie Ray Watts
Vice President of High-Throughput Chemistry
Heiko Runz
Vice President for Neuroscience/Genetics
Nan Zhang
Head of Biometrics
06 · Company updates
Updates from insitro
Recent articles published on insitro's official website.
insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design
Read on insitroIntroducing insitro’s TherML™: Rapidly engineering the right therapeutic for the right target
Read on insitroinsitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
Read on insitroRewriting the Playbook for ALS Drug Development
Read on insitroinsitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery
Read on insitro07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.